Last checked at 26 Sep 2014 07:00
Proteome Sciences plc
Excellent Toxicity Results for PS110 and PS278-05 in Alzheimer's disease
26th September 2014. Proteome Sciences is very pleased to announce that the two external in vitro toxicity safety tests (Ames and Cyp) have shown no adverse data for either of the two lead compounds, PS110 and PS278-05 for its CK1d programme which has demonstrated the modification of the tau pathway in Alzheimer's disease.
Given the current strong pharma interest in secretases, initially gamma secretase and lately beta secretase (BACE) this entirely unrelated series gives another powerful approach to potential Alzheimer therapies.
These lead molecules have shown in vivo activity in a relevant mouse model and much mechanistic data has been collected confirming the validity of tau as a target in the treatment of this problematic dementia which is seen as one of the key areas for governmental support. We are also reporting the completion of the first SysQuant® study in CNS which has shown that our CK1d compounds have successfully modified certain key pathways linked with amyloid processing, oxidative phosphorylation and energy production and these have reduced tau damage in our preferred in vivo mouse model.
Our aim was to achieve data that reflected efficacy, to provide early safety data and to ensure that the patent portfolio was strong. With this CK1d portfolio we are ready to move into the next stage of marketing to progress the outlicensing programme with pharma following on from the presentations made at the Alzheimer's Association International Conference (AAIC) in July. Our strategy is to partner the CK1d compounds with pharma on the back of these results.
Dr Ian Pike, COO commented:
"This is an important milestone in the pre-clinical development of potent and selective inhibitors of a key protein involved in Alzheimer's disease progression. Our most recent data has shown the power of SysQuant® global phosphoproteomic analysis to identify multiple beneficial effects of our compounds in tau and amyloid-related pathology. After receiving this clean set of toxicity results we believe our compounds are compelling candidates for outlicensing to established pharmaceutical companies."
"
- Ends -
For further information please contact:
Proteome Sciences plc | |
Christopher Pearce, Executive Chairman | Tel: +44 (0)1932 865065 |
Dr. Ian Pike, Chief Operating Officer | |
James Malthouse, Finance Director | |
Nominated Adviser | |
Cenkos | |
Stephen Keys/Callum Davidson/Mark Connelly finnCap Geoff Nash | Tel: +44 (0)20 7397 8900
Tel : +44 (0)20 7220 0563 |
Public Relations | |
IKON Associates | Email: adrian@ikonassociates.com |
Adrian Shaw | Tel: +44 (0)1483 271291 |
Mobile +44(0)7979 900733 | |
Notes for editors:
About Proteome Sciences plc (www.proteomics.com)
Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. The Company is headquartered in Cobham, UK, with laboratory facilities in London and Frankfurt.
Proteome Sciences' proprietary research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers in Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or have already been outlicensed.
The Company's PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to pharmaceutical, biotechnology and diagnostics companies from its ISO 9001: 2008 facility in Frankfurt, Germany.